Erasca, Inc.

60 articles with Erasca, Inc.

• Erasca Announces Poster Presentation at the 2023 AACR Annual MeetingPoster will feature preliminary Phase 1 dose escalation data for potential best-in-class SHP2 inhibitor ERAS-601 in combination with cetuximab

  3/14/2023

  Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the company will present a poster presentation at the upcoming American Association for Cancer Research Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

• Erasca to Present at the Guggenheim Oncology Conference 2023

  2/1/2023

  Erasca, Inc. today announced its participation in the Guggenheim Oncology Conference 2023. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat beginning at 1:00 pm Eastern Time on Wednesday, February 8, 2023.

• Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Erasca, Inc. announced its participation in the 41st annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California.

• Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors

  12/20/2022

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient in the HERKULES-1 Phase 1b trial evaluating ERK1/2 inhibitor ERAS-007 in combination with SHP2 inhibitor ERAS-601 (together, Erasca’s first MAPKlamp) in patients with RAS/MAPK pathway-altered solid tumors.

• Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

  12/13/2022

  Erasca, Inc. today announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-3490.

• Erasca Announces Pricing of Underwritten Offering of Common Stock - December 09, 2022

  12/9/2022

  Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share.

• Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

  12/9/2022

  Erasca, Inc. (Nasdaq: ERAS) today announced it has entered into an exclusive worldwide license agreement with Novartis (NYSE: NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRAS mutant (NRASm) melanoma and other RAS/MAPK pathway-driven tumors.

• Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

  11/30/2022

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pierre Fabre for the BRAF inhibitor encorafenib (BRAFTOVI®) within key international territories.

• Erasca to Present at Upcoming Investor Conferences

  11/22/2022

  Erasca, Inc. today announced that company management will present at the following investor conferences.

• Erasca Reports Third Quarter 2022 Financial Results and Business Updates

  11/9/2022

  Erasca, Inc. reported financial results for the fiscal quarter ended September 30, 2022, and provided business updates.

• 

  Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing (Updated)

  10/20/2022

  Erasca announced that it was expanding its existing partnership with Pfizer to assess its ERAS-007 in combination with the Big Pharma’s Ibrance.

• Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

  10/20/2022

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. (NYSE: PFE) for the CDK4/6 inhibitor palbociclib (IBRANCE®).

• Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium

  10/12/2022

  Erasca, Inc. (Nasdaq: ERAS) today announced four poster presentations at the 34th EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics taking place October 26-28 in Barcelona, Spain.

• Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022

  9/26/2022

  Erasca, Inc. today announced its participation in the Bank of America Securities Precision Oncology Conference.

• Erasca to Present at the Morgan Stanley Global Healthcare Conference - September 09, 2022

  9/9/2022

  Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced its participation in the Morgan Stanley Global Healthcare Conference.

• Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials

  9/7/2022

  Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.

• Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors

  8/24/2022

  Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601.

• Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers

  8/23/2022

  Erasca, Inc. (Nasdaq: ERAS), and The University of Texas MD Anderson Cancer Center (MD Anderson), today announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway as either single-agent or combination therapies.

• Erasca Reports Second Quarter 2022 Financial Results and Business Updates

  8/11/2022

  Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported financial results for the fiscal quarter ended June 30, 2022, and provided business updates.

• Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

  7/18/2022

  Erasca, Inc. today announced that it has entered into a clinical trial collaboration and supply agreement (CTCSA) with Eli Lilly and Company for Lilly’s anti-EGFR antibody cetuximab (ERBITUX®).